Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration

Clifford R Jr. Jack, Heather J. Wiste, David S Knopman, Prashanthi D Vemuri, Michelle M Mielke, Stephen D. Weigand, Matthew L. Senjem, Jeffrey L. Gunter, Val Lowe, Brian E. Gregg, Vernon S. Pankratz, Ronald Carl Petersen

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Objective: To test the hypotheses predicted in a hypothetical model of Alzheimer disease (AD) biomarkers that rates of β-amyloid (Ab) accumulation on PET imaging are not related to hippo-campal neurodegeneration whereas rates of neurodegenerative brain atrophy depend on the presence of both amyloid and neurodegeneration in a population-based sample. Methods: A total of 252 cognitively normal (CN) participants from the Mayo Clinic Study of Aging had 2 or more serial visits with both amyloid PET and MRI. Subjects were classified into 4 groups based on baseline positive/negative amyloid PET (A+ or A-) and baseline hippocampal volume (N+ or N-). We compared rates of amyloid accumulation and rates of brain atrophy among the 4 groups. Results: At baseline, 148 (59%) were amyloid negative and neurodegeneration negative (A-N-), 29 (12%) amyloid negative and neurodegeneration positive (A-N+), 56 (22%) amyloid positive and neurodegeneration negative (A+N-), and 19 (8%) amyloid positive and neurodegeneration positive (A+N+). High rates of Aβ accumulation were found in those with abnormal amyloid at baseline and were not influenced by hippocampal neurodegeneration at baseline. In contrast, rates of brain atrophy were greatest in A+N+. Conclusions: We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging-Alzheimer's Association preclinical staging criteria. Our results support 2 key concepts in a model of the temporal evolution of AD bio-markers. First, the rate of Ab accumulation is not influenced by neurodegeneration and thus may be a biologically independent process. Second, Aβ pathophysiology increases or catalyzes neurodegeneration.

Original languageEnglish (US)
Pages (from-to)1605-1612
Number of pages8
JournalNeurology
Volume82
Issue number18
DOIs
StatePublished - May 6 2014

Fingerprint

Amyloid
Atrophy
Alzheimer Disease
Brain
National Institute on Aging (U.S.)
Biomarkers

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. / Jack, Clifford R Jr.; Wiste, Heather J.; Knopman, David S; Vemuri, Prashanthi D; Mielke, Michelle M; Weigand, Stephen D.; Senjem, Matthew L.; Gunter, Jeffrey L.; Lowe, Val; Gregg, Brian E.; Pankratz, Vernon S.; Petersen, Ronald Carl.

In: Neurology, Vol. 82, No. 18, 06.05.2014, p. 1605-1612.

Research output: Contribution to journalArticle

Jack, Clifford R Jr. ; Wiste, Heather J. ; Knopman, David S ; Vemuri, Prashanthi D ; Mielke, Michelle M ; Weigand, Stephen D. ; Senjem, Matthew L. ; Gunter, Jeffrey L. ; Lowe, Val ; Gregg, Brian E. ; Pankratz, Vernon S. ; Petersen, Ronald Carl. / Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. In: Neurology. 2014 ; Vol. 82, No. 18. pp. 1605-1612.
@article{ca9c28ea8b7f4045b63aca8abf4b5b13,
title = "Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration",
abstract = "Objective: To test the hypotheses predicted in a hypothetical model of Alzheimer disease (AD) biomarkers that rates of β-amyloid (Ab) accumulation on PET imaging are not related to hippo-campal neurodegeneration whereas rates of neurodegenerative brain atrophy depend on the presence of both amyloid and neurodegeneration in a population-based sample. Methods: A total of 252 cognitively normal (CN) participants from the Mayo Clinic Study of Aging had 2 or more serial visits with both amyloid PET and MRI. Subjects were classified into 4 groups based on baseline positive/negative amyloid PET (A+ or A-) and baseline hippocampal volume (N+ or N-). We compared rates of amyloid accumulation and rates of brain atrophy among the 4 groups. Results: At baseline, 148 (59{\%}) were amyloid negative and neurodegeneration negative (A-N-), 29 (12{\%}) amyloid negative and neurodegeneration positive (A-N+), 56 (22{\%}) amyloid positive and neurodegeneration negative (A+N-), and 19 (8{\%}) amyloid positive and neurodegeneration positive (A+N+). High rates of Aβ accumulation were found in those with abnormal amyloid at baseline and were not influenced by hippocampal neurodegeneration at baseline. In contrast, rates of brain atrophy were greatest in A+N+. Conclusions: We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging-Alzheimer's Association preclinical staging criteria. Our results support 2 key concepts in a model of the temporal evolution of AD bio-markers. First, the rate of Ab accumulation is not influenced by neurodegeneration and thus may be a biologically independent process. Second, Aβ pathophysiology increases or catalyzes neurodegeneration.",
author = "Jack, {Clifford R Jr.} and Wiste, {Heather J.} and Knopman, {David S} and Vemuri, {Prashanthi D} and Mielke, {Michelle M} and Weigand, {Stephen D.} and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Val Lowe and Gregg, {Brian E.} and Pankratz, {Vernon S.} and Petersen, {Ronald Carl}",
year = "2014",
month = "5",
day = "6",
doi = "10.1212/WNL.0000000000000386",
language = "English (US)",
volume = "82",
pages = "1605--1612",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration

AU - Jack, Clifford R Jr.

AU - Wiste, Heather J.

AU - Knopman, David S

AU - Vemuri, Prashanthi D

AU - Mielke, Michelle M

AU - Weigand, Stephen D.

AU - Senjem, Matthew L.

AU - Gunter, Jeffrey L.

AU - Lowe, Val

AU - Gregg, Brian E.

AU - Pankratz, Vernon S.

AU - Petersen, Ronald Carl

PY - 2014/5/6

Y1 - 2014/5/6

N2 - Objective: To test the hypotheses predicted in a hypothetical model of Alzheimer disease (AD) biomarkers that rates of β-amyloid (Ab) accumulation on PET imaging are not related to hippo-campal neurodegeneration whereas rates of neurodegenerative brain atrophy depend on the presence of both amyloid and neurodegeneration in a population-based sample. Methods: A total of 252 cognitively normal (CN) participants from the Mayo Clinic Study of Aging had 2 or more serial visits with both amyloid PET and MRI. Subjects were classified into 4 groups based on baseline positive/negative amyloid PET (A+ or A-) and baseline hippocampal volume (N+ or N-). We compared rates of amyloid accumulation and rates of brain atrophy among the 4 groups. Results: At baseline, 148 (59%) were amyloid negative and neurodegeneration negative (A-N-), 29 (12%) amyloid negative and neurodegeneration positive (A-N+), 56 (22%) amyloid positive and neurodegeneration negative (A+N-), and 19 (8%) amyloid positive and neurodegeneration positive (A+N+). High rates of Aβ accumulation were found in those with abnormal amyloid at baseline and were not influenced by hippocampal neurodegeneration at baseline. In contrast, rates of brain atrophy were greatest in A+N+. Conclusions: We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging-Alzheimer's Association preclinical staging criteria. Our results support 2 key concepts in a model of the temporal evolution of AD bio-markers. First, the rate of Ab accumulation is not influenced by neurodegeneration and thus may be a biologically independent process. Second, Aβ pathophysiology increases or catalyzes neurodegeneration.

AB - Objective: To test the hypotheses predicted in a hypothetical model of Alzheimer disease (AD) biomarkers that rates of β-amyloid (Ab) accumulation on PET imaging are not related to hippo-campal neurodegeneration whereas rates of neurodegenerative brain atrophy depend on the presence of both amyloid and neurodegeneration in a population-based sample. Methods: A total of 252 cognitively normal (CN) participants from the Mayo Clinic Study of Aging had 2 or more serial visits with both amyloid PET and MRI. Subjects were classified into 4 groups based on baseline positive/negative amyloid PET (A+ or A-) and baseline hippocampal volume (N+ or N-). We compared rates of amyloid accumulation and rates of brain atrophy among the 4 groups. Results: At baseline, 148 (59%) were amyloid negative and neurodegeneration negative (A-N-), 29 (12%) amyloid negative and neurodegeneration positive (A-N+), 56 (22%) amyloid positive and neurodegeneration negative (A+N-), and 19 (8%) amyloid positive and neurodegeneration positive (A+N+). High rates of Aβ accumulation were found in those with abnormal amyloid at baseline and were not influenced by hippocampal neurodegeneration at baseline. In contrast, rates of brain atrophy were greatest in A+N+. Conclusions: We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging-Alzheimer's Association preclinical staging criteria. Our results support 2 key concepts in a model of the temporal evolution of AD bio-markers. First, the rate of Ab accumulation is not influenced by neurodegeneration and thus may be a biologically independent process. Second, Aβ pathophysiology increases or catalyzes neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=84902166246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902166246&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000000386

DO - 10.1212/WNL.0000000000000386

M3 - Article

C2 - 24706010

AN - SCOPUS:84902166246

VL - 82

SP - 1605

EP - 1612

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 18

ER -